Adlai Nortye Group (ANL) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Kura Oncology (KURA) over the past year, gaining 818.8% versus a gain of 3.4%. Adlai Nortye Group is the larger company by market cap ($1.01 billion vs $943.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | KURA |
|---|---|---|
| Share price | $15.62 | $10.60 |
| Market cap | $1.01B | $942.98M |
| 1-day change | +0.71% | +0.76% |
| YTD return | +1000.00% | +2.02% |
| 1-year return | +818.82% | +3.41% |
| 5-year return | — | -41.18% |
| EPS (TTM) | $-0.66 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $13.90 |
| 52-week low | $0.879 | $7.36 |
| Distance from 52-week high | -9.45% | -23.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.86% | +200.47% |
| Average volume | 188.39K | 1.78M |
| Shares outstanding | 58.73M | 88.96M |
| Employees | 109 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed KURA by 815.4 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
ANL vs KURA FAQ
Which is bigger, Adlai Nortye Group or Kura Oncology?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $1.01B compared with $942.98M for Kura Oncology (KURA).
Which stock has performed better over the past year, ANL or KURA?
ANL returned +818.82% over the past 12 months, compared with +3.41% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.